6533b7d9fe1ef96bd126cd9e
RESEARCH PRODUCT
Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.
Tina SedmakSabine ReydaUwe WolfrumBodo PlachterSteffi AueTobias BoppJürgen PodlechSina I. SchaderSabine BeckeDoris Thomassubject
Human cytomegalovirusCD4-Positive T-Lymphocytesvirusesmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusMice TransgenicBiologyCD8-Positive T-LymphocytesAntibodies ViralVirusCell LineViral Matrix ProteinsCytomegalovirus VaccinesMiceAntigenmedicineCytotoxic T cellAnimalsHumansNeutralizing antibodyAntigens ViralMice Inbred BALB CGeneral VeterinaryGeneral Immunology and MicrobiologyPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseasePhosphoproteinsVirologyAntibodies NeutralizingMutagenesis InsertionalInfectious DiseasesCytomegalovirus InfectionsDNA Viralbiology.proteinMolecular MedicineAdjuvantCD8description
Control of human cytomegalovirus (HCMV) infection correlates with the reconstitution of antiviral T lymphocytes in haematopoietic stem cell transplant recipients. A vaccine to foster this reconstitution and to ameliorate the severe consequences of HCMV reactivation is yet unavailable. This work focused on providing a rationale for the amendment of the yields and the antigenic composition of a vaccine, based on subviral dense bodies (DB) of HCMV. Modified DB were generated that contained the HLA-A2 presented IE1 model peptide TMYGGISLL, integrated at different positions in the major DB protein pp65. Insertion at position W175 of pp65 allowed efficient formation of recDB in the cytoplasm of infected cells and resulted in considerable yields of these particles. Even in the absence of adjuvant, these particles proved to be highly immunogenic with respect to CD8 and CD4 T cell and neutralizing antibody responses.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-01-14 | Vaccine |